Full Coverage

Depomed Starts Hot Flash Phase III for Gabapentin GR

                   
tmcnet.com
Sep 17, 2008
        
Story Timeline:  78 days

Alternative to Hormones? Depomed Inc. initiated the first of two pivotal trials for menopausal hot flashes with Gabapentin GR, an extended-release version of the active ingredient in Pfizer Inc.'s marketed seizure and pain drug, Neurontin. Menlo Park, Calif.-based Depomed is hoping its drug may offer an alternative to estrogen-based hormone replacement therapy (HRT), which was linked to an increased risk of... [read full story]                    

Add Comment
Latest article on this story:

Depomed initiates Phase III menopausal hot flashes program

 pharmaceutical-business-review.com Sep 19, 2008
First article on this story:

Depomed starts late-stage test of hot flash drug (at bizjournals.com)

 yahoo.com Sep 17, 2008
Selected publications with coverage of this story:
pharmaceutical-business-review.com redorbit.com yahoo.com euroinvestor.co.uk tmcnet.com finanznachrichten.de
RELATED
Found 5 documents:

Depomed initiates Phase III menopausal hot flashes program

pharmaceutical-business-review.com
Sep 19, 2008
        

Depomed, a specialty pharmaceutical company, has announced the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase III clinical trials in Depomed's registration program for Gabapentin...

Depomed to Present at the UBS Global Life Sciences Conference (Business Wire)

yahoo.com
Sep 19, 2008
        

MENLO PARK, Calif.----Depomed, Inc. today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference...

Depomed to Present at the UBS Global Life Sciences Conference

redorbit.com
Sep 18, 2008
        

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be...

Depomed to Present at the UBS Global Life Sciences Conference

finanznachrichten.de
Sep 18, 2008
        

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be...

Depomed starts late-stage test of hot flash drug (at bizjournals.com)

yahoo.com
Sep 17, 2008
        

started a Phase III test of an extended release version of a drug for menopausal hot flashes. This will be the first of two Phase III trials for the drug, Gabapentin GR. It’s a new formulation of an already approved drug...